Clinical Trial Detail

NCT ID NCT00942331
Title Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

urethra cancer

urethra transitional cell carcinoma

prostate transitional cell carcinoma

prostate cancer

ureter cancer

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

bladder carcinoma

Therapies

Bevacizumab + Cisplatin + Gemcitabine

Cisplatin + Gemcitabine

Age Groups: adult

No variant requirements are available.